


# **Adipose tissue autophagy in obesity – Contributes to, or protects from, morbidity?**

**Assaf Rudich**


**Ben-Gurion University** 

**Be'er-Sheva, Israel**



**Sunrise, Lahav  
Photo: Zvia Rudich**

# Understanding the intriguing phenotype of the insulin-sensitive obese



## The insulin-sensitive obese:

- \* Lower systemic inflammation: *Lower hsCRP, lower systemic IL-6*
- \* Fat distribution: *less Visceral fat, more superficial SC fat*
- \* Lower fat deposition in non-adipose tissue/adipocytes (ectopic fat = fatty liver)
- \* Increased reliance on adipocyte hyperplasia
- \* Less adipose tissue inflammation and fibrosis

Blüher: Am J Physiol – Endocrinol and Metab 299: E506, 2010;

Golan: Diabetes Care 35: 640, 2012

# How does “stressed fat” become dysfunctional?

Insulin sensitive





Insulin resistant



BMI = ~45 Kg/m<sup>2</sup>

Omental  
(visceral) fat



100µm

**“Angry fat”!!**  
- Stressed  
- Dysfunctional



## Stresses:



Oxidative      ER  
Inflammatory    Hypoxic  
Metabolic



## Dysfunctional:

Dys-regulated lipolysis  
Insulin resistant  
Abnormal secreted products

# Human adipose tissue stress response in obesity



**"Angry fat"!!**  
- Stressed  
- Dysfunctional




*Endocrinology, 148:2955, 2007*

*Trends Endocrinol. Metab., 18: 291, 2007*

*J. Clin. Endocrinol. Metab., 94, 2507, 2009.*


# Increased protein levels of autophagy genes in omental (visceral) fat in obesity

## Obese





# Questions:

1. Is autophagic FLUX up-regulated in adipose tissue in human obesity? Is this unique to adipose tissue?
2. What is the mechanism for autophagy activation in adipose tissue in obesity?
3. What might be the functional/ (pathophysiological) role of such activation? - Is adipose tissue autophagy “good” or “bad”?




# Autophagic flux is activated (1):

more increase in LC3II, p62 and NBR1 with inhibitors



## Autophagic flux is activated (2):

Higher number of LC3-dots (autophagosomes) in human fat explants





### Autophagy in obesity:

Enhanced in *human* adipose tissue, BUT Inhibited in *mouse* liver!

- Mouse Vs human difference?
- Adipose Vs liver difference?

# Autophagy in liver and fat in obesity:


A tissue-difference, not a human-mouse difference



# Autophagy in liver and fat in obesity:

A tissue-difference, not a human-mouse difference

Change in autophagy gene expression by 16w high fat feeding in mice



# Questions:

1. Is autophagic FLUX up-regulated in adipose tissue in human obesity? Is this unique to adipose tissue?

**YES** (even if oppositely-regulated in other tissues!!):

- *Mol Med* 16: 235, 2010.
- *JCEM* 9: E268, 2011; *Obesity Facts* 5: 710, 2012.
- *Endocrinology* 153: 5866, 2012.
- *Nunez et al, Int. J. Obesity* 2013, *in press*, PMID:23478428



**NO:**

- Suppressed in mice: *BBRC* 417, 352, 2012

# Questions:

1. Is autophagic FLUX up-regulated in adipose tissue in human obesity? Is this unique to adipose tissue?
2. What is the mechanism for autophagy activation in adipose tissue in obesity?
3. What might be the functional/ (pathophysiological) role of such activation?


# Is Atg's mRNA increased?



|                                 | <b>Lean<br/>(n=66)</b> | <b>SC-Obese<br/>(n=88)</b> | <b>IA-Obese<br/>(n=42)</b> |
|---------------------------------|------------------------|----------------------------|----------------------------|
| Age                             | 50.3 ± 2.1             | 57.8 ± 1.5 *               | 59.1 ± 2.0 ^               |
| Sex (% male)                    | 48                     | 47                         | 53                         |
| BMI (Kg/m <sup>2</sup> )        | 24.2 ± 0.2             | 34.6 ± 0.6 *               | 33.1 ± 0.8 ^               |
| Fat area (cm <sup>2</sup> )     |                        |                            |                            |
| SC                              | 55.3 ± 2.8             | 851.9 ± 32.3 *             | 416.1 ± 24.1 #             |
| IA (visceral)                   | 56.6 ± 2.8             | 165.7 ± 4.4 *              | 294.5 ± 8.5 #              |
| Mean adipocyte diameter (μm)    |                        |                            |                            |
| SC                              | 94.2 ± 1.1             | 106.6 ± 0.9 *              | 112.9 ± 2.0 #              |
| OM                              | 85.0 ± 0.7             | 99.6 ± 0.7 *               | 104.5 ± 0.9 #              |
| Fasting plasma glucose (mmol/l) | 5.8 ± 0.1              | 5.7 ± 0.1                  | 5.7 ± 0.1                  |
| Fasting plasma insulin (pmol/l) | 57.5 ± 12.0            | 175.7 ± 13.3 *             | 193.8 ± 16.6 ^             |
| GIR (μmol/Kg/min)               | 82.3 ± 3.6             | 59.0 ± 2.7 *               | 37.1 ± 3.2 #               |
| HbA1C (%)                       | 5.5 ± 0.1              | 5.7 ± 0.1 *                | 5.9 ± 0.1 #                |



Matthias Blüher, University of Leipzig, Germany

# mRNA levels of key autophagy genes are increased in human OM fat in obesity



*Is autophagy regulated transcriptionally??*

# Human adipose tissue stress response in obesity – *inspiration from literature:*



**"Angry fat"!!**  
- Stressed  
- Dysfunctional




*Endocrinology, 148:2955, 2007*

*Trends Endocrinol. Metab., 18: 291, 2007*

*J. Clin. Endocrinol. Metab., 94, 2507, 2009.*


*J. Clin. Endocrinol. Metab., 96, E268, 2011.*

# Transcriptional-based regulation of autophagy: Loss-of-function approach




Yulia Haim, unpublished data

# Transcriptional-based regulation of autophagy: gain-of-function approach




HEK 293 cells




Julia Kovsan, unpublished data

# Transcriptional-based regulation of autophagy: gain-of-function approach




Julia Kovsan, unpublished data

# Sensitization to TNF $\alpha$ of several autophagy gene promoters by E2F1 over-expression: Dual luciferase assay




Plasmids: Kind gift from **Eun-Kyeong Jo**, Chungnam National University School of Medicine, Daejeon, South Korea;; **Kenichi Yoshida**, Meiji University, Kanagawa, Japan.


# Higher expression of *E2F1* in omental (visceral) fat associates with *ASK1* and *Atg5* expression (but not *Ki67*)



Human samples n=500  
Matthias Blüher, Leipzig




# Protein expression of E2F1 *vis-à-vis* ASK1 and autophagy genes in human adipose tissue





Tanya Tarnovscki, unpublished data

# A chromatin immunoprecipitation (ChIP) protocol for use in whole human adipose tissue

Yulia Haim,<sup>1</sup> Tanya Tarnovscki,<sup>1</sup> Dana Bashari,<sup>2</sup> and Assaf Rudich<sup>1,3</sup>



LC3B promoter:



# Questions:

2. What is the mechanism for autophagy/autophagy gene expression up-regulation in adipose tissue in obesity?


## Our suggestion:

- Transcriptionally-based;
- Direct, and/or by sensitizing the tissue to stress

# Questions:

1. Is autophagic FLUX up-regulated in adipose tissue in human obesity? Is this unique to adipose tissue?
2. What is the mechanism for autophagy/autophagy gene expression up-regulation in adipose tissue in obesity?
3. What might be the functional/ (pathophysiological) role of such activation? - Is adipose tissue autophagy “good” or “bad”?

# Adipose tissue autophagy early in the course of obesity-associated cardio-metabolic morbidity



|                                 | Insulin sensitive obese (n=30) | Insulin resistant obese (n=30) |
|---------------------------------|--------------------------------|--------------------------------|
| Age                             | 44.6 ± 0.4                     | 44.9 ± 0.4                     |
| Sex (% male)                    | 33                             | 37                             |
| BMI (Kg/m <sup>2</sup> )        | 45.1 ± 0.2                     | 45.2 ± 0.2                     |
| Fasting plasma glucose (mmol/l) | 5.2 ± 0.0                      | 5.7 ± 0.1*                     |
| Fasting plasma insulin          | 29.8 ± 2.6                     | 104.7 ± 5.6*                   |
| GIR (μmol/Kg/min)               | 89.4 ± 1.7                     | 33.0 ± 2.5*                    |
| HbA1C (%)                       | 5.3 ± 0.0                      | 5.7 ± 0.1*                     |


- **Normoglycemic**
- **No CV disease**

Obese -/+ Insulin resistant

GIR – glucose infusion rate;


*J Clin. Endocrinol. Metab. 96: E268, 2011*

# Omental fat autophagy activation co-appears with insulin resistance, but precedes obesity-associated morbidity!





But when it is activated – does it act to limit disease progression, or does it contribute to pathogenesis?

# Activated autophagy is potentially protective: 3MA-mediated autophagy inhibition in human fat explants enhances pro-inflammatory cytokines secretion/expression



# Activated autophagy is potentially detrimental: Inhibiting adipose tissue autophagy prevents hepatocyte insulin resistance in a fat-hepatocyte co-culture system



# Questions:

1. Is autophagic FLUX up-regulated in adipose tissue in human obesity? Is this unique to adipose tissue?
2. What is the mechanism for autophagy/autophagy gene expression up-regulation in adipose tissue in obesity?
3. What might be the functional/ (pathophysiological) role of such activation? - Is adipose tissue autophagy “good” or “bad”?

The “jury is still out”:

- Autophagy may limit further adipose inflammation. But,
- May be involved in adipocyte insulin resistance and dysfunctional fat-liver crosstalk!

# Thanks to:

## BGU

- Nava Bashan

-- Iris Shai

- Yulia Haim

- Tanya Tarnovscki

- Noa Slutsky

- Ori Nov

- Ilana Harman-Boehm

- Boris Kirshtein

- Julia Kovsan

## BIU

- Doron Ginsberg

## WIS

- Zevi Elazar

- Michael Walker

GIF, BSF, ISF, Israeli ministry of Health

... and thanks for your attention!

## Leipzig, Germany

- Matthias Blüher

- Nora Kloting

## Columbus, OH

- Gustavo Leone

## Zurich, Switzerland

- Daniel Konrad

- Stephan Wuest


## Daejeon, Korea

- Eun-Kyeong Jo


Sde-Boker, Negev

(Photo: Zvia Rudich)


# Inhibition of autophago-lysosome function protects against adipocyte TNF-induced insulin resistance.




# *E2F1* mRNA in subcutaneous (SC) and omental (Om) human adipose tissue



# Loss of function approach to prove causality




# *E2F1* mRNA in subcutaneous (SC) and omental (Om) human adipose tissue




# Higher expression of E2F1 in omental (visceral) fat associates with a more morbid obese phenotype


Basic Characteristics



Adipose Characteristics









Metabolic/ endocrine



Quintiles of Om-E2F1 mRNA

Q1  
Q2  
Q3  
Q4  
Q5

n=500



# **Summary & possible conclusions:**


1. “Angry fat” exhibits increased E2F1 expression, at both the mRNA and protein levels.
2. In human adipose tissue, E2F1 correlates with ASK1 and autophagy genes, and exhibits BMI- correlated increased binding to their promoters.
3. In cells, increased E2F1 expression:
  - i. induces ASK1 and Atg's expression;
  - ii. plays a permissive/sensitizing role for their induction by inflammatory and oxidative stress signals.
4. In the absence of E2F1, adipocyte-like MEFs exhibit decreased basal and inflammation-induced ASK1 and Autophagy.

→ **E2F1 may be a co-regulator of two arms of the adipose stress signaling cascade in obesity, activating and sensitizing them to inflammatory and oxidative stress.**


# What about other E2Fs?

□ SC  
■ OM


E2F1 (n=196)



E2F3 (n=130)




E2F4 (n=130)



# E2F1 over-expression:

- i. activates the human ASK1 promoter,
- ii is permissive for inflammation-induced promoter activation.




ASK1 promoter activity in HEK293 cells


Yulia Haim, unpublished data

# E2F1 binding site in the ASK1 promoter includes a -384 bp site

Mutational analysis of the ASK1 promoter (ChIP) sequence in the hASK1 promoter




ASK1 promoter activity assay




*Unpublished data*

# JNK-phosphorylation based input on ASK1 promoter activity


|              |   |   |   |   |   |   |
|--------------|---|---|---|---|---|---|
| pCMV         | + | + | - | - | - | - |
| pCMV-E2F1    | - | - | + | + | + | + |
| TNF $\alpha$ | - | + | - | + | - | + |
| SP 600125    | - | - | - | - | + | + |



# E2F1 and JNK phosphorylation-based activation of ASK1 promoter




# ASK1 promoter activation by over-expression of E2F1, E2F2, E2F3, E2F4 and their combinations






# Stress signaling in Intra-abdominal fat in human obesity: *Ask1* is an upstream component




*Endocrinology*, 148:2955, 2007

*Trends Endocrinol. Metab.*, 18: 291, 2007

*J. Clin. Endocrinol. Metab.*, 94, 2507, 2009.




# Stress signaling in Intra-abdominal fat in human obesity: *Ask1* is an upstream component




*Endocrinology*, 148:2955, 2007

*Trends Endocrinol. Metab.*, 18: 291, 2007

*J. Clin. Endocrinol. Metab.*, 94, 2507, 2009.



# Phosphorylation and transcription -based regulation of ASK1 (MAP3K5)




# *OM-Ask1 mRNA level is an independent predictor of whole-body insulin resistance*

| <u>Dependent variable:</u> Glucose infusion rate (GIR) during clamp  | <u>Standard coefficients</u><br><u>(Beta)</u> | <u>Significance</u> |
|--|---|---------------------|
| <u>Model 1:</u> Age-adjusted<br>OM-Ask1<br>SC-Ask1   | -0.547<br>-0.021                              | <0.001<br>0.797     |
| <u>Model 2:</u> Adjusted for Age, Sex, BMI<br>OM-Ask1<br>SC-Ask1   | -0.526<br>0.002                               | <0.001<br>0.983     |
| <u>Model 3:</u> Adjusted for Age, Sex, BMI, HDL-c, LDL-c, TG, FFA<br>OM-Ask1<br>SC-Ask1                            | -0.336<br>-0.100                              | <0.001<br>0.894     |
| <u>Model 4:</u> Adjusted for Age, Sex, BMI, HDL-c, LDL-c, TG, FFA, leptin, adiponectin, IL-6<br>OM-Ask1<br>SC-Ask1 | -0.308<br>-0.009                              | 0.001<br>0.913      |



# Transcriptional activation of *ASK1* in intra-abdominal adipocytes cell line: potential role of inflammation and oxidative stress

## Intra-abdominal adipocyte cell line




# Transcriptional activation of *ASK1* in intra-abdominal adipocytes: potential role of inflammation and oxidative stress

SGBS human pre-adipocytes




Intra-abdominal (mouse) adipocytes



*Unpublished data*









# AP is activated (3):

**mRNA levels of key autophagy genes are increased in human OM fat in obesity, particularly if fat is accumulated intra-abdominally!**



# E2F1 is required for basal and inflammation-induced stress signaling and autophagy

MEFs - Fibroblasts      MEFs – adipocyte like



*Unpublished data*


# Superficial subcutaneous fat – - metabolically-safe place to store excess calories!

WC – 110 cm

33.6%

26.2%

38%




WC – 112 cm


14.5%

27.2%

53.7%



■ Superficial SC fat  
■ Deep SC fat





# **Take home messages before we go on:**

1. Visceral fat accumulation is associated with a more detrimental cardio-metabolic obesity sub-phenotype than accumulation of subcutaneous fat.
2. Adipose tissue expansion by adipocyte hypertrophy is more detrimental than expansion by hyperplasia.
3. Accumulation of superficial subcutaneous fat, a depot likely expanding predominantly by hyperplasia, may be cardio-metabolically protective.
4. “Angry fat” is more hypertrophic (larger cells), inflamed and fibrotic, and may become dysfunction by mounting a “tissue stress response”.

**→ What is the molecular makeup of *human* adipose tissue stress response?**



# Autophagy in liver and fat in obesity:

## A tissue-difference, not a human-mouse difference




# AP is activated (1):

more increase in LC3II, p62 and NBR1 with inhibitors





## AP is activated (2):

Higher number of LC3-dots (autophagosomes) in human fat explants



# Autophagy in liver and fat in obesity:

## A tissue-difference, not a human-mouse difference



# Gain of function approach to prove causality

